$8.11
+0.87%Oct 26, 2026, 14:45 UTC
Grifols SA began a phased reopening of its Canadian plasma collection operations on October 20, 2026, with two centres operating at reduced capacity.
Source:Oct 20, 2026, 16:45 UTC
Grifols SA reopened its plasma donation facility in Edmonton with limited appointments as part of a phased return to operations.
Source:Oct 20, 2026, 16:45 UTC
Grifols SA reopened its Innovation Drive plasma donation centre in Winnipeg with limited appointments as part of a phased return to operations.
Source:Oct 16, 2026, 19:00 UTC
Grifols SA and allied health coalitions called on the federal government to close Grifols’ paid-plasma centres, terminate the contract between Canadian Blood Services and Grifols, and launch an independent federal inquiry into deaths connected to Grifols locations in Winnipeg.
Source:Oct 8, 2026, 22:00 UTC
The Grifols SA donated $25,000 to Feed the Boro to support about 10 months of food for its monthly food drops.
Source:Sep 23, 2026, 21:51 UTC
Optimi Health Corp. completed and quality-released a production batch of 5mg naturally derived psilocybin capsules at its cGMP facility in Princeton, British Columbia, to supply a Health Canada-approved Phase 2 MDD trial and commercial customers in Australia.
Source:Sep 23, 2026, 21:45 UTC
Health Canada suspended Grifols's licence for its Taylor Avenue plasma collection centre in Winnipeg effective immediately, citing an ineffective quality management system.
Source:Sep 16, 2026, 11:15 UTC
A Health Canada inspection of a Regina plasma centre run by Grifols found multiple donors were allowed to donate without proper medical assessments, including a donor who disclosed sexual contact with someone with HIV/AIDS and was inappropriately allowed to donate twice.
Source:Sep 14, 2026, 22:45 UTC
Grifols replaced Barzin Bahardoust as sole director of Grifols Canada Plasma Corporation with three Grifols executives based in Canada, the United States and Spain on Sept. 1, 2026.
Source:Aug 13, 2026, 20:45 UTC
Grifols temporarily paused plasma collection at all its donation centres across Canada.
Aug 10, 2026, 11:00 UTC
Grifols announced the completion of the clinical portion of its Phase 3 SPARTA study evaluating Prolastin-C in patients with emphysema due to alpha-1 antitrypsin deficiency.
Source:Jul 16, 2026, 12:00 UTC
Grifols dosed first patients in two Phase 3 trials to expand indications for its immunoglobulins GAMUNEX-C and XEMBIFY.
Source:Jul 15, 2026, 23:59 UTC
Health Canada flagged concerns in an inspection of Grifols' head office, including inappropriate clearance of donors with Creutzfeldt-Jakob Disease risk factors.
Jul 3, 2026, 11:45 UTC
Grifols reorganizes its operating model into a dual structure, separating its US plasma division from the rest of the world, with executive changes including the departure of Roland Wandeler.
Source:Jul 3, 2026, 11:45 UTC
Roland Wandeler will leave Grifols on 30 September to pursue new professional projects.
Source: